What is the price target for SXTP stock?
8 analysts have analysed SXTP and the average price target is 17.95 USD. This implies a price increase of 880.98% is expected in the next year compared to the current price of 1.83.
60 DEGREES PHARMA INC (SXTP) Forecast, Price Target & Analyst Ratings
NASDAQ:SXTP • US83006G5009
Current stock price
1.83 USD
-0.12 (-6.15%)
At close:
1.8401 USD
+0.01 (+0.55%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 60 DEGREES PHARMA INC (SXTP).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$2.33
- Revenue Estimate
- 545.7K
Price Target Details & History
Consensus Price Target and Range
Mean target
$17.95
Upside
+ 880.98%
From current price of $1.83 to mean target of $17.95, Based on 8 analyst forecasts
Low
$11.31
Median
$17.95
High
$25.20
Price Target Revisions
1 Month
0.00%
3 Months
300.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for SXTP. The average price target is 17.95 USD. This implies a price increase of 880.98% is expected in the next year compared to the current price of 1.83.
The average price target has been revised upward by 300% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
SXTP was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SXTP.
In the previous month the buy percentage consensus was at a similar level.
SXTP was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-28 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-09-03 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-02 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-23 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-04-03 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-10-20 | HC Wainwright & Co. | Initiate | Neutral |
| 2023-10-02 | Ascendiant Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$2.33
- Revenue Estimate
- 545.7K
- Revenue Q2Q
- 136.23%
- EPS Q2Q
- 95.91%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-300.00%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2025 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 511.2K -91.95% | 253.6K -50.39% | 681.4K 168.69% | 1.678M 146.26% | 2.091M 24.61% | 3.857M 84.46% | 3.06M -20.66% | |
| EBITDA YoY % growth | -1.718M -57.10% | -5.104M -197.18% | -9.665M -89.34% | -8.568M 11.35% | -8.262M 3.57% | N/A | N/A | |
| EBIT YoY % growth | -1.75M -55.72% | -5.155M -194.48% | -9.715M -88.47% | -8.201M 15.59% | -8.109M 1.12% | -5.881M 27.47% | -9.792M -66.49% | |
| Operating Margin | -342.41% | -2,032.57% | -1,425.73% | -488.72% | -387.80% | -152.48% | -320.00% | |
| EPS YoY % growth | N/A | N/A | -152.80 30.26% | -13.02 91.48% | -7.04 45.92% | -0.48 93.19% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.33 95.91% | -1.88 69.92% | -2.00 60.02% | -2.00 24.27% | -2.12 8.77% |
| Revenue Q2Q % growth | 545.7K 136.23% | 408K 150.31% | 408K 32.52% | 408K -22.81% | 510K -6.54% |
| EBITDA Q2Q % growth | -2.55M -25.89% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.877M 9.59% | -1.877M 1.78% | -1.979M -23.31% | -1.979M 14.91% | -2.122M -13.04% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.93%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
82.46%
Revenue Next 5 Year
48.16%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
60 DEGREES PHARMA INC / SXTP Forecast FAQ
What are the consensus estimates for 60 DEGREES PHARMA INC (SXTP) next earnings?
The consensus EPS estimate for the next earnings of 60 DEGREES PHARMA INC (SXTP) is -2.33 USD and the consensus revenue estimate is 545.70K USD.
What is the expected long term growth rate for SXTP stock?
The expected long term growth rate for 60 DEGREES PHARMA INC (SXTP) is 82.46%.